Targeting the PI3-Kinase/Akt/mTOR Signaling Pathway

Burhan Hassan; Argun Akcakanat; Ashley M. Holder; Funda Meric-Bernstam

doi:10.1016/j.soc.2013.06.008

Targeting the PI3-Kinase/Akt/mTOR Signaling Pathway

Burhan Hassan, Argun Akcakanat, Ashley M. Holder, Funda Meric-Bernstam

Research output: Contribution to journal › Review article › peer-review

157 Scopus citations

Abstract

This article presents an overview of the PI3K/Akt/mTOR signaling pathway. As a central regulator of cell growth, protein translation, survival, and metabolism, activation of this signaling pathway contributes to the pathogenesis of many tumor types. Biochemical and genetic aberrations of this pathway observed in various cancer types are explored. Last, pathway inhibitors both in development and already approved by the Food and Drug Administration are discussed.

Original language	English (US)
Pages (from-to)	641-664
Number of pages	24
Journal	Surgical Oncology Clinics of North America
Volume	22
Issue number	4
DOIs	https://doi.org/10.1016/j.soc.2013.06.008
State	Published - Oct 2013

Keywords

Cell signaling
Molecular targeted therapy
PI3K/Akt/mTOR signaling pathway
PTEN

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1016/j.soc.2013.06.008

Cite this

@article{a61cfbb325334448baef0a7b6be4e41b,

title = "Targeting the PI3-Kinase/Akt/mTOR Signaling Pathway",

abstract = "This article presents an overview of the PI3K/Akt/mTOR signaling pathway. As a central regulator of cell growth, protein translation, survival, and metabolism, activation of this signaling pathway contributes to the pathogenesis of many tumor types. Biochemical and genetic aberrations of this pathway observed in various cancer types are explored. Last, pathway inhibitors both in development and already approved by the Food and Drug Administration are discussed.",

keywords = "Cell signaling, Molecular targeted therapy, PI3K/Akt/mTOR signaling pathway, PTEN",

author = "Burhan Hassan and Argun Akcakanat and Holder, {Ashley M.} and Funda Meric-Bernstam",

note = "Funding Information: Conflict of Interest: Funda Meric-Bernstam has research funding from AstraZeneca and Celgene. Funding Information: Funding Sources: This work was supported in part by the National Cancer Institute T32 CA009599-23 (A.M.H, F.M.B), Susan G. Komen for the Cure SAC10006 (F.M.B), Stand Up to Cancer Dream Team Translational Research Grant, a Program of the Entertainment Industry Foundation ( SU2C-AACR-DT0209 ) (F.M.B, A.A), National Cancer Institute 5R21 CA159270 , the Kleberg Center for Molecular Markers at The University of Texas MD Anderson Cancer Center , the National Center for Research Resources Grants 3UL1RR024148 and UL1TR000371 (F.M.B and A.A). ",

year = "2013",

month = oct,

doi = "10.1016/j.soc.2013.06.008",

language = "English (US)",

volume = "22",

pages = "641--664",

journal = "Surgical Oncology Clinics of North America",

issn = "1055-3207",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Targeting the PI3-Kinase/Akt/mTOR Signaling Pathway

AU - Hassan, Burhan

AU - Akcakanat, Argun

AU - Holder, Ashley M.

AU - Meric-Bernstam, Funda

N1 - Funding Information: Conflict of Interest: Funda Meric-Bernstam has research funding from AstraZeneca and Celgene. Funding Information: Funding Sources: This work was supported in part by the National Cancer Institute T32 CA009599-23 (A.M.H, F.M.B), Susan G. Komen for the Cure SAC10006 (F.M.B), Stand Up to Cancer Dream Team Translational Research Grant, a Program of the Entertainment Industry Foundation ( SU2C-AACR-DT0209 ) (F.M.B, A.A), National Cancer Institute 5R21 CA159270 , the Kleberg Center for Molecular Markers at The University of Texas MD Anderson Cancer Center , the National Center for Research Resources Grants 3UL1RR024148 and UL1TR000371 (F.M.B and A.A).

PY - 2013/10

Y1 - 2013/10

N2 - This article presents an overview of the PI3K/Akt/mTOR signaling pathway. As a central regulator of cell growth, protein translation, survival, and metabolism, activation of this signaling pathway contributes to the pathogenesis of many tumor types. Biochemical and genetic aberrations of this pathway observed in various cancer types are explored. Last, pathway inhibitors both in development and already approved by the Food and Drug Administration are discussed.

AB - This article presents an overview of the PI3K/Akt/mTOR signaling pathway. As a central regulator of cell growth, protein translation, survival, and metabolism, activation of this signaling pathway contributes to the pathogenesis of many tumor types. Biochemical and genetic aberrations of this pathway observed in various cancer types are explored. Last, pathway inhibitors both in development and already approved by the Food and Drug Administration are discussed.

KW - Cell signaling

KW - Molecular targeted therapy

KW - PI3K/Akt/mTOR signaling pathway

KW - PTEN

UR - http://www.scopus.com/inward/record.url?scp=84883551219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883551219&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2013.06.008

DO - 10.1016/j.soc.2013.06.008

M3 - Review article

C2 - 24012393

AN - SCOPUS:84883551219

VL - 22

SP - 641

EP - 664

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

SN - 1055-3207

IS - 4

ER -

Targeting the PI3-Kinase/Akt/mTOR Signaling Pathway

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this